Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Drug Therapy01:28

Drug Therapy

30
The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications
30
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

316
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
316
Factors Affecting Drug Response: Overview01:21

Factors Affecting Drug Response: Overview

1.7K
When it comes to infants and young children, they are typically administered smaller doses of medication in comparison to adults. This is primarily because their organ functions still need to fully develop, meaning their bodies are not as efficient at metabolizing or eliminating drugs. Additionally, their blood-brain barrier is more permeable than in adults. As a result, high concentrations of drugs can easily penetrate the central nervous system (CNS), potentially leading to neurological...
1.7K
Cholinergic Antagonists: Therapeutic Uses01:26

Cholinergic Antagonists: Therapeutic Uses

669
Antimuscarinic drugs have various therapeutic applications by inhibiting parasympathetic stimulation in different systems. Here are the key therapeutic uses of antimuscarinics:    
Respiratory Tract: Ipratropium, aclidinium, and tiotropium treat asthma, chronic bronchitis, and chronic obstructive pulmonary disease (COPD). They protect against bronchoconstriction caused by irritants like cigarette smoke, sulfur dioxide, and ozone. They also help reduce nasopharyngeal...
669
Heart Failure Drugs: Diuretics01:22

Heart Failure Drugs: Diuretics

291
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
291
Cholinergic Antagonists: Pharmacological Actions01:28

Cholinergic Antagonists: Pharmacological Actions

730
Antimuscarinic drugs block muscarinic receptors in multiple systems, including the gut, eye, smooth muscles, respiratory tract, cardiovascular, and central nervous systems. They produce similar effects with varying selectivity depending on the specific agent and tissue. Here are the key pharmacological actions of antimuscarinics:
Gastrointestinal Effects: Antimuscarinics reduce gut contractions, increase gastric emptying, and slow intestinal transit. They partly inhibit gastric acid secretion...
730

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A Global Consensus Conference on Surgical Management of Primary Uterovaginal Prolapse and Lower Urinary Tract Dysfunction: Combining Evidence with Expert Opinion.

International urogynecology journal·2026
Same author

Unequal Utilization of Overactive Bladder Treatment: The Role of Socioeconomic and Insurance Disparities.

Neurourology and urodynamics·2026
Same author

Patients' Perspectives and Challenges with Sacral Neuromodulation Implantable Pulse Generator.

International urogynecology journal·2026
Same author

Polypropylene mesh degradation and systemic disease: biological plausibility is not clinical evidence.

Nature reviews. Urology·2026
Same author

Navigating the challenges of overactive bladder management in women.

World journal of urology·2026
Same author

Seventy-Five Years of NIH NIDDK Funding Has Increased Knowledge and Greatly Impacted Clinical Care.

Neurourology and urodynamics·2026
Same journal

Cardiovascular Prevention in Older Adults: From Estimation to Treatment.

Clinics in geriatric medicine·2026
Same journal

Preventive Cardiology for the Clinically Complex Older Adult.

Clinics in geriatric medicine·2026
Same journal

A Preventive Neurology Perspective on Promoting Brain Health and Preventing Cardiovascular Disease.

Clinics in geriatric medicine·2026
Same journal

Secondary Prevention in Older Adults: Putting It All Together.

Clinics in geriatric medicine·2026
Same journal

Primary Prevention in Older Adults: Putting It All Together.

Clinics in geriatric medicine·2026
Same journal

Managing Bleeding Risk in Older Adults: Antithrombotics and Anticoagulants.

Clinics in geriatric medicine·2026
See all related articles

Related Experiment Video

Updated: May 12, 2025

Detrusor Underactivity Model in Rats by Conus Medullaris Transection
03:26

Detrusor Underactivity Model in Rats by Conus Medullaris Transection

Published on: August 28, 2020

2.0K

Overactive Bladder Medications in Geriatrics-Risks and Realities.

Tyler Trump1, Howard B Goldman1

  • 1Department of Urology, Glickman Urological Institute, Cleveland Clinic Foundation, 9500 Euclid Avenue/Q10, Cleveland, OH 44195, USA.

Clinics in Geriatric Medicine
|May 9, 2025
PubMed
Summary
This summary is machine-generated.

Overactive bladder treatments like anti-cholinergics are linked to serious side effects in older adults. Beta-3 agonists offer a safer alternative with fewer adverse events for managing overactive bladder.

Keywords:
AnticholinergicBeta-3 agonistDementiaFallsGeriatricOveractive bladder

More Related Videos

Real-Time Void Spot Assay
06:39

Real-Time Void Spot Assay

Published on: February 10, 2023

1.8K
Evaluation of Biomaterials for Bladder Augmentation using Cystometric Analyses in Various Rodent Models
10:19

Evaluation of Biomaterials for Bladder Augmentation using Cystometric Analyses in Various Rodent Models

Published on: August 9, 2012

19.2K

Related Experiment Videos

Last Updated: May 12, 2025

Detrusor Underactivity Model in Rats by Conus Medullaris Transection
03:26

Detrusor Underactivity Model in Rats by Conus Medullaris Transection

Published on: August 28, 2020

2.0K
Real-Time Void Spot Assay
06:39

Real-Time Void Spot Assay

Published on: February 10, 2023

1.8K
Evaluation of Biomaterials for Bladder Augmentation using Cystometric Analyses in Various Rodent Models
10:19

Evaluation of Biomaterials for Bladder Augmentation using Cystometric Analyses in Various Rodent Models

Published on: August 9, 2012

19.2K

Area of Science:

  • Gerontology
  • Pharmacology
  • Urology

Background:

  • Overactive bladder (OAB) is a prevalent condition, particularly in the elderly.
  • Anti-cholinergic medications have long been the primary treatment for OAB.
  • Recent research raises concerns about the safety of anti-cholinergic therapies.

Purpose of the Study:

  • To review the literature on the risks associated with OAB pharmacologic therapies.
  • To compare the safety profiles of anti-cholinergics and beta-3 agonists for OAB treatment.

Main Methods:

  • Literature review of studies on overactive bladder treatments.
  • Analysis of adverse events associated with anti-cholinergics and beta-3 agonists.
  • Examination of pharmacologic properties influencing risk profiles.

Main Results:

  • Anti-cholinergics are associated with cognitive decline, falls, fractures, and increased mortality.
  • Certain anti-cholinergic formulations present higher risks due to specific properties.
  • Beta-3 agonists have not demonstrated similar adverse event associations.

Conclusions:

  • The safety profile of OAB treatments is a critical consideration, especially for the elderly.
  • Beta-3 agonists represent a potentially safer alternative to anti-cholinergics for OAB management.
  • Further research into OAB therapeutic risks is warranted to optimize patient care.